Fig. 3.

Cervical cancers averted by routine one-dose HPV vaccination as a proportion of cervical cancers averted by routine HPV vaccination programmes conferring lifelong protection at 100% vaccine efficacy. The median percentage (intervals: 10–90th percentile) of cancers averted by a one-dose schedule compared to a two-dose programme of the 10 model-country settings: the HSA model in black, HPV-ADVISE model-country pairs in red, and the Harvard model-country pairs in blue. Health outcomes were discounted at 0%. Only cervical cancers caused by HPV 16, 18, 31, 33, 45, 52, and 58, which could be averted by the 9-valent HPV vaccine, were considered